 CytoDyn Inc announced more progress for its leronlimab candidate as a treatment for HIV, saying it has now submitted all the major sections of the chemistry, manufacturing, and controls CMC to the Food Drug Administration FDA - the US regulator. This CMC is a critical part of the biotechs Biologics License Application BLA for HIV - the request for permission to commercialize a product. 